HOV O 8 2004 TO SEE TRADEMARK

JAW

Docket No. PRD2053USNP

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Brett Allison

Serial No.: 10/811,292

Art Unit: 1614

Filed

: March 26, 2004

Examiner:

For

: BENZO[1,2,5]THIADIAZOLE COMPOUNDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

November 5, 2004
(Date of Deposit)

John W. Harbour (Name of applicant, assignee, or Registered Representative)

November 5, 2004

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with  the
first or  Second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
The considerate with \$1.07(a) this Information
☐ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or

Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
<u> </u>
☐ In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
☐ If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2053/JWH. This form is submitted in triplicate.

Respectfully submitted,

John W. Harbour

/Reg. No. 31,365

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2169

DATED: November 5, 2004

NOV 0 8 2004 P. Substitute for

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control numb

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	valid UMB control number.
Application Number	10/811,292
Filing Date	March 26, 2004
First Named Inventor	Brett Allison
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	PRD2053USNP

	Cite No.1	U.S. Patent Document  Kind Code <sup>2</sup> Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
Examiner Initials						
		6,239,131		Shinozaki, K., et al.(Zeria Pharmaceutical Co., Ltd.	05-29-2001	
					17	

LLC DATENT DOCUMENTS

#### FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite Т6 mm-dd-yyyy Applicant of Cited Document figures appear Initials Office<sup>3</sup> Number<sup>4</sup> KindCode<sup>5</sup> WO 04013087 Makovec, F. et al. (Rotta Research 02-12-2004 Laboratorium)

Examiner	Dat	ate
Signature	Coi	onsidered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

8 2004 E

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a collection of information unless it displays a valid OMB control number.		
10/811,292		
March 26, 2004		
Brett Allison		
1614		
PRD2053USNP		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	2
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Initials*	No.1	publisher, city and/or country where published	
		Black, J.W. and S.B. Kalindjian. Gastrin Agonists and Antagonists. Pharmacol. Toxicol. (2002) 91:275-281.	
		de Tullio, P. et al. Therapeutic and Chemical Developments of Cholecystokinin Receptor Ligands. Exp. Opin. Invest. Drugs (2000) 9(1):129-146.	
		Herranz, R. Cholecystokinin Antagonists: Pharmacological and Therapeutic Potential. Med. Res. Rev. (2003) 23(5):559-605.	
		Revel, L. and F. Makovec. Update on Nonpeptide CCK-B Receptor Antagonists. Drugs Future. (1998) 23(7):751-766.	
		McDonald, I.M. CCK2 Receptor Antagonists. Exp. Opin. Ther. Patents. (2001) 11(3):445-462.	
		Morton, M.F. et al. Pharmacological Comparison of the Alternatively Spliced Short and Long CCK2 Receptors. Br. J. Pharmacol. (2003) 140(1):218-224.	
		Tracy, H.J. and R.A. Gregory. Physiological Properties of a Series of Peptides Structurally Related to Gastrin 1. Nature (London). (1964) 204:935-938.	
		Varnavas, A. et al. Anthranilic Acid Based CCK1 Antagonists: The 2-Indole Moiety May Represent a "Needle" According to the Recent Homonymous Concept. Eur. J. Med. Chem. (2004) 39:85-97.	
		Varnavas, A. et al. Anthranilic Acid Derivatives: A New Class of Non-Peptide CCK1 Receptor Antagonists. Bioorg. Med. Chem. (2003) 11:741-751.	
		Varnavas, A. et al. Synthesis of N-Terminal Substituted Anthranilic Acid Dimer Derivatives for Evaluation on CCK Receptors. II Farmaco. (2001) 56:555-564.	
			-
-			

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.